Brought to you by 
Astellas signs $760mm deal for beta-secretase inhibitors; CTS21166 program terminated; entire deal ended
17 Oct 2014
Executive Summary
CoMentis (formerly Athenagen; focuses on neurovascular disorders) has licensed Astellas Pharma exclusive worldwide rights to its Phase I Alzheimer's disease candidate CTS21166 plus others in its beta-secretase inhibitor program. The companies also agreed to research future molecules in this class.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Astellas signs $760mm deal for beta-secretase inhibitors; CTS21166 program terminated; entire deal ended
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice